Pathogen antigen (via antibody binding and neutralization)

This entry refers not to a discrete molecular target (such as a specific receptor, enzyme, or single pathogen protein), but to the general concept of pathogen (or antigen) neutralization by antibody binding. In this process, antibodies generated by the adaptive immune system bind specific antigens (proteins, carbohydrates, or other molecules) on the surface of pathogens (bacteria, viruses, toxins), preventing them from interacting with host cell receptors and thus neutralizing their infectivity or toxicity[1][3][6]. The neutralizing antibody–antigen complex may then be cleared by immune cells or, in some cases, inactivate the pathogen directly[2][4][5]. Antibody-based therapeutics exploit this mechanism by providing exogenous monoclonal antibodies that target known pathogen antigens. However, as “pathogen/antigen” is not itself a molecular entity but a broad category, this is not a canonical “target” in the pharmacological or molecular sense, and is too generic or non-specific for structured therapeutic target databases[1][3][6]. Key point: “Pathogens/antigens via antibody binding and neutralization” describes a broad immune mechanism against diverse pathogens, not a distinct molecular target. The correct approach is to specify the concrete antigen (e.g., “SARS-CoV-2 spike glycoprotein,” “HIV-1 Env glycoprotein,” “diphtheria toxin”) being neutralized by the antibody[1][3][7].

Other names

Pathogenantigenmicrobial antigenviral antigenbacterial antigentoxin (as antibody targets)

Antibody-mediated neutralization—where an antibody binds a pathogen/antigen, inactivating it, preventing host cell entry or replication, or marking it for immune clearance[1][2][3][5][6]